Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27319730 | 0.88 | FAAH (0.41) | FAAHNPSR1GLO1ALDH1A1TSHR | |
| SCHEMBL4974869 | 0.88 | FAAH (0.57) | FAAHNPSR1GLO1ALDH1A1TSHR | |
| SCHEMBL21641889 | 0.85 | FAAH (0.68) | FAAHALDH1A1TSHRLMNASMN1; SMN2 | |
| SCHEMBL20477114 | 0.85 | FAAH (0.68) | FAAHALDH1A1TSHRLMNASMN1; SMN2 | |
| SCHEMBL410005 | 0.82 | ALDH1A1 (0.42) | FAAHNPSR1GLO1ALDH1A1TSHR | |
| SCHEMBL18863964 | 0.81 | TSHR (0.40) | FAAHNPSR1ALDH1A1TSHRLMNA | |
| SCHEMBL6382743 | 0.81 | FAAH (0.53) | FAAHNPSR1GLO1ALDH1A1TSHR | |
| SCHEMBL16046274 | 0.79 | FAAH (0.53) | FAAHNPSR1GLO1ALDH1A1TSHR | |
| SCHEMBL5402287 | 0.78 | ALDH1A1 (0.48) | FAAHALDH1A1TSHRLMNASMN1; SMN2 | |
| SCHEMBL4527336 | 0.78 | NPSR1 (0.43) | FAAHNPSR1GLO1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981820-B | Method for synthesizing quinoxaline-2-ketone under acidic condition | 上海彩迩文生化科技有限公司 | 2023-05-19 | — | — | CN | claimed |
| US-20260102525-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | SILBER B MICHAEL (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250255992-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | REILEY PHARMACEUTICALS INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-20240358866-A1 | NSAID-DERIVED CONJUGATE COMPOUNDS FOR IMAGING | REILEY PHARMACEUTICALS INC (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024118818-A1 | NSAID-DERIVED CONJUGATE COMPOUNDS FOR IMAGING | Reiley Pharmaceuticals, Inc. (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4247817-A1 | MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-116670140-A | Macrocyclic compounds containing 1,3, 4-oxadiazole rings as modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4225384-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | Reiley Pharmaceuticals, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116406368-A | Conjugated compounds derived from sibs and methods of use thereof | 赖利制药公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-2618665-A1 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | MSD ITALIA SRL (IT) | 2013-07-11 | — | — | US | disclosed |
| WO-2012040040-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-7947683-B2 | 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMTED (GB) | 2011-05-24 | — | — | US | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| EP-2086982-A1 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| WO-2008057209-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1869017-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006108701-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | FAAH 1933/4885NPSR1 4083/4885GLO1 1213/4885 |
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, HTR3C, TACR2 | FAAH 1909/4885NPSR1 79/4885GLO1 4152/4885 |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, CTSC, GTF3C3 | FAAH 1717/4885NPSR1 4173/4885GLO1 1127/4885 |
| US-20250255992-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | PTGES2, PTGES, OPRK1 | FAAH 535/4885NPSR1 1898/4885GLO1 874/4885 |
| US-20260102525-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | OPRK1, OPRD1, OPRM1 | FAAH 444/4885NPSR1 2223/4885GLO1 3827/4885 |
| US-20240358866-A1 | NSAID-DERIVED CONJUGATE COMPOUNDS FOR IMAGING | PTGES2, PTGS2, PTGES | FAAH 456/4885NPSR1 316/4885GLO1 1612/4885 |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | FAAH 3786/4885NPSR1 3829/4885GLO1 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.